Theradiag

Theradiag FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Theradiag (ALTER.PA) as of Oct 22, 2026 is 196.86 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 43.55 % — a change of 352.02% (higher).

FCF Conversion

196.86 %

YoY

352.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Theradiag is 2018 196.86 % . FCF Conversion Rate (FCF/EBITDA) of Theradiag was 2017 43.55 % . It decreases by 352.02% higher compared to the previous year.

The Theradiag FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
118.92 EUR
Jan 1, 2015
120.45 EUR
Jan 1, 2016
130.52 EUR
Jan 1, 2017
43.55 EUR
Jan 1, 2018
196.86 EUR
The Theradiag FCF Conversion history
YEARFCF ConversionYoY
196.86 %+352.02%
43.55 %-66.63%
130.52 %+8.36%
120.45 %+1.28%
118.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Theradiag Stock analysis

What does Theradiag do? Theradiag SA is a French company specialized in the development, production, and marketing of diagnostics for personalized medicine. The company was founded in 1986 and is headquartered in Marne-la-Vallée, France. It is listed on the stock exchange and belongs to the Euronext Growth market segment. Theradiag offers diagnostics for autoimmune, infectious, cancer, and inflammatory diseases. Its business model involves developing innovative diagnostics and selling them to clinical laboratories and hospitals. The company has a network of distributors to sell its products globally. Its offerings include diagnostics for autoimmune diseases, infections, cancer, and inflammation, as well as personalized medicine. The company invests in research and development to improve patients' health and well-being. Theradiag is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Theradiag stock

FCF Conversion Rate (FCF/EBITDA) of Theradiag is 196.86 % in 2018.

FCF Conversion Rate (FCF/EBITDA) of Theradiag changed from 43.55 % to 196.86 %, representing a 352.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Theradiag since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Theradiag with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Theradiag

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Theradiag